About Mediator of RNA polymerase II transcription subunit 27
Mediator of RNA polymerase II transcription subunit 27 (MED27) is a protein
from Homo sapiens identified by UniProt accession
Q6P2C8, 311 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Mediator of RNA polymerase II transcription subunit 27 |
|---|
| UniProt accession | Q6P2C8 |
|---|
| Gene | MED27 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 311 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia · score 0.73
- Intellectual disability · score 0.55
- Dystonia · score 0.53
- Axial hypotonia · score 0.53
- epilepsy · score 0.53
- Cataract · score 0.53
- Cerebellar hypoplasia · score 0.53
- Spasticity · score 0.53
- neurodegenerative disease · score 0.46
- self reported educational attainment · score 0.38
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6P2C8-F1 | alphafold | PREDICTED | 82.42 | — |
Amino-acid sequence (311 residues)
MADVINVSVN LEAFSQAISA IQALRSSVSR VFDCLKDGMR NKETLEGREK AFIAHFQDNL HSVNRDLNEL ERLSNLVGKP SENHPLHNSG LLSLDPVQDK TPLYSQLLQA YKWSNKLQYH AGLASGLLNQ QSLKRSANQM GVSAKRRPKA QPTTLVLPPQ YVDDVISRID RMFPEMSIHL SRPNGTSAML LVTLGKVLKV IVVMRSLFID RTIVKGYNEN VYTEDGKLDI WSKSNYQVFQ KVTDHATTAL LHYQLPQMPD VVVRSFMTWL RSYIKLFQAP CQRCGKFLQD GLPPTWRDFR TLEAFHDTCR Q
Explore Mediator of RNA polymerase II transcription subunit 27 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets